anastrozole has been researched along with Osteoporosis, Postmenopausal in 14 studies
Osteoporosis, Postmenopausal: Metabolic disorder associated with fractures of the femoral neck, vertebrae, and distal forearm. It occurs commonly in women within 15-20 years after menopause, and is caused by factors associated with menopause including estrogen deficiency.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this bone substudy, bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at baseline and after 12- and 24-month treatment in 63 patients receiving Anastrozole as adjuvant treatment for hormone receptor-positive early breast cancer." | 9.17 | Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole. ( Hadji, P; Hars, O; Kalder, M; Knöll, D; Kyvernitakis, I; Ziller, V, 2013) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 9.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "6 mg every 28 days subcutaneously) +/- zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin +/- zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer." | 9.12 | Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. ( Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M, 2007) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 7.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "Anastrozole induced an increase in bone remodelling: osteocalcin (+36." | 6.73 | Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. ( Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F, 2007) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 5.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 5.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| " 3 year) in postmenopausal women with breast cancer previously treated with 2-3 years of tamoxifen." | 5.30 | Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study. ( de Boer, M; de Graaf, H; de Roos, WK; Erdkamp, FLG; Honkoop, AH; Imholz, ALT; Kroep, JR; Linn, SC; Peer, PGM; Seynaeve, CM; Smorenburg, CH; Swinkels, ACP; Tjan-Heijnen, VCG; van den Berkmortel, FWPJ; van der Sangen, MJC; van Hellemond, IEG, 2019) |
| "In this bone substudy, bone mineral density (BMD) was assessed by dual energy X-ray absorptiometry at baseline and after 12- and 24-month treatment in 63 patients receiving Anastrozole as adjuvant treatment for hormone receptor-positive early breast cancer." | 5.17 | Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole. ( Hadji, P; Hars, O; Kalder, M; Knöll, D; Kyvernitakis, I; Ziller, V, 2013) |
| "PURPOSE To investigate the management of bone health in women with early breast cancer (EBC) who were scheduled to receive anastrozole." | 5.14 | Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. ( Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C, 2010) |
| "The aim of this multicenter, phase III, prospective open label clinical trial was to investigate the effect of risedronate (R) on bone mineral density (BMD) in postmenopausal, early breast cancer (BC) patients scheduled to receive anastrozole (A)." | 5.14 | Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. ( Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2010) |
| "6 mg every 28 days subcutaneously) +/- zoledronic acid (4 mg intravenously every 6 months) versus anastrozole (1 mg/d orally) and goserelin +/- zoledronic acid for 3 years in premenopausal women with hormone-responsive breast cancer." | 5.12 | Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. ( Galid, A; Gnant, MF; Grampp, S; Hausmaninger, H; Jakesz, R; Kaessmann, H; Luschin-Ebengreuth, G; Menzel, C; Mittlboeck, M; Mlineritsch, B; Piswanger-Soelkner, JC; Schmid, M, 2007) |
| "The aim of this study was to assess the effect of adjuvant anastrozole, alone or associated with risedronate, on BMD and bone fracture risk in women more than 70 years old with hormone receptor-positive early breast cancer (EBC)." | 3.78 | Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer. ( Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N, 2012) |
| "The aim of this study was to determine whether the bone-resorption response to anastrozole differed according to initial patient age in postmenopausal women with breast cancer in a cross-sectional study." | 3.77 | Does anastrozole affect bone resorption similarly in early and late postmenopausal women? ( Cochrane, RA; Davie, MW; Powell, DE, 2011) |
| "Anastrozole induced an increase in bone remodelling: osteocalcin (+36." | 2.73 | Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. ( Brun, J; Confavreux, CB; Delmas, PD; Fontana, A; Guastalla, JP; Munoz, F, 2007) |
| "Postmenopausal women with early breast cancer (EBC) are already at risk for bone loss, osteoporosis and fracture as they age because of declining estrogen levels." | 2.46 | Women and bone health: maximizing the benefits of aromatase inhibitor therapy. ( Tang, SC, 2010) |
| "In patients with mild or severe osteopenia or osteoporosis, treated with A + R, no age effect was observed for LS or HP (p = 0." | 1.38 | Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial. ( Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V, 2012) |
| "The primary end point is breast cancer incidence, but major efforts are also being directed at minimizing any fracture risk." | 1.35 | IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. ( Cuzick, J, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lipton, A | 1 |
| Chapman, JW | 1 |
| Leitzel, K | 1 |
| Garg, A | 1 |
| Pritchard, KI | 1 |
| Ingle, JN | 1 |
| Budd, GT | 1 |
| Ellis, MJ | 1 |
| Sledge, GW | 1 |
| Rabaglio, M | 1 |
| Han, L | 1 |
| Elliott, CR | 1 |
| Shepherd, LE | 1 |
| Goss, PE | 2 |
| Ali, SM | 1 |
| van Hellemond, IEG | 1 |
| Smorenburg, CH | 1 |
| Peer, PGM | 1 |
| Swinkels, ACP | 1 |
| Seynaeve, CM | 1 |
| van der Sangen, MJC | 1 |
| Kroep, JR | 1 |
| de Graaf, H | 1 |
| Honkoop, AH | 1 |
| Erdkamp, FLG | 1 |
| van den Berkmortel, FWPJ | 1 |
| de Boer, M | 1 |
| de Roos, WK | 1 |
| Linn, SC | 1 |
| Imholz, ALT | 1 |
| Tjan-Heijnen, VCG | 1 |
| Kalder, M | 1 |
| Ziller, V | 1 |
| Kyvernitakis, I | 1 |
| Knöll, D | 1 |
| Hars, O | 1 |
| Hadji, P | 1 |
| Cuzick, J | 1 |
| Van Poznak, C | 1 |
| Hannon, RA | 1 |
| Mackey, JR | 1 |
| Campone, M | 1 |
| Apffelstaedt, JP | 1 |
| Clack, G | 1 |
| Barlow, D | 1 |
| Makris, A | 1 |
| Eastell, R | 1 |
| Markopoulos, C | 2 |
| Tzoracoleftherakis, E | 2 |
| Polychronis, A | 1 |
| Venizelos, B | 2 |
| Dafni, U | 1 |
| Xepapadakis, G | 2 |
| Papadiamantis, J | 1 |
| Zobolas, V | 2 |
| Misitzis, J | 2 |
| Kalogerakos, K | 1 |
| Sarantopoulou, A | 1 |
| Siasos, N | 1 |
| Koukouras, D | 2 |
| Antonopoulou, Z | 1 |
| Lazarou, S | 1 |
| Gogas, H | 2 |
| Tang, SC | 1 |
| Powell, DE | 1 |
| Cochrane, RA | 1 |
| Davie, MW | 1 |
| Sergi, G | 1 |
| Pintore, G | 1 |
| Falci, C | 1 |
| Veronese, N | 1 |
| Berton, L | 1 |
| Perissinotto, E | 1 |
| Basso, U | 1 |
| Brunello, A | 1 |
| Monfardini, S | 1 |
| Manzato, E | 1 |
| Coin, A | 1 |
| Esteva, FJ | 1 |
| Hortobagyi, GN | 1 |
| Chien, AJ | 1 |
| Gnant, MF | 1 |
| Mlineritsch, B | 1 |
| Luschin-Ebengreuth, G | 1 |
| Grampp, S | 1 |
| Kaessmann, H | 1 |
| Schmid, M | 1 |
| Menzel, C | 1 |
| Piswanger-Soelkner, JC | 1 |
| Galid, A | 1 |
| Mittlboeck, M | 1 |
| Hausmaninger, H | 1 |
| Jakesz, R | 1 |
| Confavreux, CB | 1 |
| Fontana, A | 1 |
| Guastalla, JP | 1 |
| Munoz, F | 1 |
| Brun, J | 1 |
| Delmas, PD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective Randomised, Open, Multicentre, Phase III Study to Assess Different Durations of Anastrozole Therapy After 2 to 3 Years Tamoxifen as Adjuvant Therapy in Postmenopausal Women With Breast Cancer.[NCT00301457] | Phase 3 | 1,914 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Phase III-IV, Multicenter Open Label Trial of Arimidex Alone Versus Arimidex Plus Bisphosphonates in Postmenopausal Patients With Early, Endocrine Positive Breast Cancer.[NCT00809484] | 220 participants (Actual) | Observational | 2004-05-31 | Completed | |||
| Metabolic and Bone Changes After Adjuvant Cancer Treatments in Early Non-metastatic Breast Cancer - a 5-year Follow-up Study.[NCT03784651] | 120 participants (Anticipated) | Observational | 2018-12-17 | Recruiting | |||
| Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid, in Premenopausal, Hormone Receptor-positive Breast Cancer Patients (Stage I, II)[NCT00295646] | Phase 3 | 1,803 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for anastrozole and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Women and bone health: maximizing the benefits of aromatase inhibitor therapy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast | 2010 |
Comparative assessment of lipid effects of endocrine therapy for breast cancer: implications for cardiovascular disease prevention in postmenopausal women.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
Aromatase inhibitors and bone health in women with breast cancer.
Topics: Absorptiometry, Photon; Algorithms; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Ar | 2006 |
7 trials available for anastrozole and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor-positive breast cancer: NCIC CTG MA.27.
Topics: Aged; Anastrozole; Androstadienes; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Ne | 2017 |
Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Female; Fractures, Bon | 2019 |
Influence of compliance on bone mineral density changes in postmenopausal women with early breast cancer on Anastrozole.
Topics: Absorptiometry, Photon; Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Che | 2013 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neop | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Densit | 2010 |
Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
Topics: Adult; Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Dip | 2007 |
Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Co | 2007 |
4 other studies available for anastrozole and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; | 2008 |
Does anastrozole affect bone resorption similarly in early and late postmenopausal women?
Topics: Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Resorption; Brea | 2011 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone De | 2012 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Densit | 2012 |